While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...
InflaRx N.V. announced that the European Commission has approved GOHIBIC® (vilobelimab) for the treatment of acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2. The company achieved a ...
People who have an inflammatory bowel disease like ulcerative colitis often have problems caused by inflammation in other parts of their bodies. One of these is a skin condition called pyoderma ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...
InflaRx N.V. (NASDAQ:IFRX) on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma ...
A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback